ArticleHealth economics review2011
The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors.
Article in Health economics review, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 44 citations in OpenAlex.
- Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study.Cost effectiveness and resource allocation : C/E · 2025Article
- The impact of periodic updates to health benefits plan: access gains without cost savings?International journal of health economics and management · 2025Article
- Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation.Cost effectiveness and resource allocation : C/E · 2020Article
- Factors influencing pharmaceutical pricing - a scoping review of academic literature in health science.Journal of pharmaceutical policy and practice · 2019Article
- Introduction of therapeutic reference pricing in Slovenia and its economic consequences.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study.Croatian medical journal · 2018Article
- Affordability of medicines in the European Union.PloS one · 2017Article
- Pharmaceutical regulation in Europe and its impact on corporate R&D.Health economics review · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study provides an overview of policy measures targeting pharmaceutical expenditure in Europe and analyses their impact on originator pharmaceutical prices. Panel data methods are used to examine the market of ACE Inhibitors in six European countries (Denmark, France, Germany, Netherlands, Sweden, United Kingdom) over period 1991-2006. We find that although some measures are effective in reducing originator prices, others appear to have an insignificant effect. Results suggest that supply side measures such as mandatory generic substitution, regressive pharmacy mark-ups and claw-backs are effective in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of cost-effectiveness analysis appear to have a negative effect on prices, while results on reference pricing are inconclusive. Findings also indicate that, although originator prices are not immediately affected by generic entry, they may be influenced by changes in generic prices post patent expiry.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.